FORMA Signs Collaboration Deal With Novartis

FORMA has entered into a collaboration agreement with Novartis. Under the terms of the agreement, FORMA will utilize its cell-based screening platform to discover inhibitors for undisclosed protein-protein interaction targets in the field of oncology.

Steven Tregay, CEO of FORMA, said: “FORMA is pleased to expand its relationship with Novartis beyond our existing agreement with the Novartis Option Fund. This collaboration provides additional validation of our fully integrated drug discovery technologies, including our transformative biology and chemistry platforms, which we will use to unlock the elusive protein-protein interaction target class that is so important to oncology drug discovery.”

FORMA is a biopharmaceutical company. It is engaged in integrating transformative biology and chemistry to unlock targets and pathways, that have been validated through genomic medicine as root causes or major drivers of human cancers.